Sarcopenia is defined as the degenerative loss of skeletal muscle mass, quality, and strength. It is associated with aging and leads to decreased body function and decreased quality of life (QOL).[@CR1] Since 2010, when the European Working Group on Sarcopenia in Older People first advocated the diagnostic criteria of sarcopenia based on muscle mass, muscle strength, and physical performance,[@CR2] sarcopenia has been acknowledged as an important factor for cancer patients as well as elderly people. Sarcopenia is associated with an elevated risk of undesirable surgical outcomes such as increased postoperative complications and prolonged hospital stay,[@CR3]^--^[@CR5] and is also associated with poor prognoses for several types of cancer.[@CR6]^--^[@CR8]

Gastric cancer is the third leading cause of cancer death and the fifth most common cancer in the world, with half of all cases occurring in Eastern Asia, including Japan.[@CR9] Advanced gastric cancer interferes with nutrition through both cancer-associated cachexia and direct obstruction to the passage of food.[@CR10] Even in early gastric cancer, decline in both weight loss and associated QOL often occur following surgery as it may reduce the stomach's capacity and consequently decrease food intake.[@CR11] For these reasons, gastric cancer may be more directly correlated with sarcopenia than many other cancers. Several studies have shown that gastric cancer patients with sarcopenia at the time of surgery experienced worse long-term outcomes than non-sarcopenic patients.[@CR12]^--^[@CR15]

In the setting of an aging population, many cancer patients receiving surgery present with a variety of comorbidities, such as hypertension, diabetes, cardiovascular disease, brain disease, respiratory disease, renal failure, and mental disorders, as well as typical age-associated declines of basic physiological functions.[@CR16] Therefore, in clinical practice we must develop treatment strategies for cancer patients that are based not only on cancer stage but also on other patient characteristics, such as age, performance status, comorbidities, and sarcopenia.

In this study, we present a retrospective investigation of the influence of sarcopenia on prognoses of gastric cancer patients who underwent gastrectomy. In addition, we assessed the influence on prognosis of the combination of sarcopenia and comorbidities, focusing particularly on non-gastric cancer-related deaths following surgery. While data related to cancer deaths tend to receive adequate attention in the medical scientific community, comparatively little consideration is given to mortality associated with non-cancer causes of death.[@CR17] We expect our findings to help inform the development of improved treatment strategies for gastric cancer patients.

Methods {#Sec1}
=======

Patients {#Sec2}
--------

We reviewed the records of 491 patients with gastric cancer who underwent gastrectomy between January 2005 and March 2014 in Okayama University Hospital for whom adequate computed tomography (CT) images taken before surgery were available. This study was approved by the Okayama University Hospital Institutional Review Board.

Definition of Sarcopenia {#Sec3}
------------------------

The total cross-sectional skeletal muscle area (SMA) at the third lumbar vertebra on preoperative CT images (Hounsfield units of − 30 to 150 for the muscle compartment) was measured using the Synapse Vincent volume analyzer (Fujifilm Medical, Tokyo, Japan) (electronic supplementary Fig. 1a). Then, for normalization, the SMA was divided by body surface area (BSA) to yield the SMA/BSA index (cm^2^/m^2^). Sarcopenia was defined as an SMA/BSA value less than the sex-specific lowest quartile of SMA/BSA; the cut-off values for males and females were 69.7 and 54.2 cm^2^/m^2^, respectively (electronic supplementary Fig. 1b).

Clinical Data {#Sec4}
-------------

Patient characteristics included age, sex, height, weight, body mass index (BMI), preoperative comorbidity, and the American Society of Anesthesiologists physical status (ASA-PS) classification. The Charlson Comorbidity Index was used for the evaluation of preoperative comorbidity,[@CR18] and a score of 1 or higher, with the exclusion of gastric cancer as a comorbidity, was defined as the presence of comorbidity. Histological type was classified into differentiated and undifferentiated, and depth of tumor invasion (T score), lymph node metastasis (N score), and stage were described according to the 3rd English edition of the Japanese Classification of Gastric Carcinoma.[@CR19] Surgical outcomes included operation procedures such as distal gastrectomy (DG), total gastrectomy (TG) and proximal gastrectomy (PG), reconstruction procedures such as Billroth-I (B-I), Roux-Y (RY) and esophagogastrostomy (EG), and operation time, blood loss, postoperative complications classified according to the Clavien--Dindo classification,[@CR20] and duration of postoperative hospital stay. Long-term survival data were obtained from medical records.

Statistical Analysis {#Sec5}
--------------------

Statistical analysis was conducted using JMP software (SAS Institute, Cary, NC, USA). Student's *t* test was used to assess the continuous variables of age and BMI, and the Wilcoxon signed-rank test was used for the other continuous variables of operation time, blood loss, and duration of hospital stay. Pearson's *χ*^2^test was used for the categorical variables of sex, comorbidity, ASA-PS, histology, T score, N score, stage, operative procedure, and incidence of postoperative complications, while the log-rank test was used for the Kaplan--Meier survival analyses. Univariate and multivariate Cox proportional hazards regression analyses were performed to assess the effects of prognostic factors on gastric cancer.

Results {#Sec6}
=======

Clinicopathological Features of Gastric Cancer Patients with Sarcopenia {#Sec7}
-----------------------------------------------------------------------

Sarcopenia was significantly associated with old age (*p*  \<  0.0001), high BMI (*p*  =  0.0344), presence of comorbidity (*p*  =  0.0150), high ASA-PS (*p*  =  0.0036), high T score (*p*  =  0.0014), advanced stage (*p*  =  0.0245), large blood loss (*p*  =  0.0012), and long hospital stay (*p*  =  0.0016) (Table [1](#Tab1){ref-type="table"}), but was not associated with postoperative complications, for which, based on univariate and multivariate analyses, age, comorbidity, and blood loss were independent risk factors (electronic supplementary Table 1).Table 1Clinicopathological features of patients with sarcopeniaNon-sarcopenia (*n*  =  368)Sarcopenia (*n*  =  123)*p* valuePatient characteristics Age, years66.6  ±  10.772.1  ±  8.4\< 0.0001 Sex, male/female (%)261/107 (71/29)87/36 (71/29)0.9676 BMI, kg/m^2^22.7  ±  3.322.0  ±  3.70.0344 Comorbidity, + (%)231 (63)92 (75)0.0150 ASA-PS ≥ III (%)23 (6)18 (15)0.0036Tumor factors (%) Histology, differentiated/undifferentiated207/160 (56/44)76/47 (62/38)0.2954 T score ≥ 2140 (38)67 (55)0.0014 N score ≥ 1116 (32)50 (41)0.0557 Stage ≥ III72 (20)36 (29)0.0245Surgical outcomes Operation procedure, DG/TG/PG/others (%)192/94/38/44 (52/26/10/12)63/36/11/13 (51/29/9/11)0.8426 Reconstruction, B-I/RY/EG/others (%)147/138/37/46 (40/38/10/13)43/50/10/20 (35/41/8/16)0.5404 Operation time, min (range)240 (200--301)240 (198--294)0.7045 Blood loss, mL (range)170 (60--410)300 (128--550)0.0012 Post-operative complications, CD ≥ I (%)80 (22)36 (29)0.0888 Post-operative complications, CD ≥ III (%)31 (8)14 (11)0.3293 Hospital stay, days (range)13 (11--16)14 (12--19)0.0016*BMI* body mass index, *ASA*-*PS* American Society of Anesthesiologists physical status, *T score* depth of tumor invasion, *N score* lymph node metastasis, *DG* distal gastrectomy, *TG* total gastrectomy, *PG* proximal gastrectomy, *B*-*I* Billroth-I, *RY* Roux-Y, *EG* esophagogastrostomy, *CD* Clavien--dindo classification

Influence of Sarcopenia on Overall Survival of Gastric Cancer Patients {#Sec8}
----------------------------------------------------------------------

Kaplan--Meier survival analysis showed that 5-year overall survival rates of sarcopenic and non-sarcopenic patients were 56 and 72%, respectively, and that sarcopenic patients had significantly poorer overall survival compared with non-sarcopenic patients (*p*  =  0.0002) (Fig. [1](#Fig1){ref-type="fig"}). Univariate and multivariate analyses revealed that sarcopenia was an independent prognostic factor for gastric cancer patients \[hazard ratio (HR) 1.46, 95% confidence interval (CI) 1.01--2.09, *p*  =  0.0454\], along with age, presence of comorbidity, histological T score, histological N score, and operation time (Table [2](#Tab2){ref-type="table"}).Fig. 1Kaplan--Meier survival curve of gastric cancer patients with sarcopenia Table 2Univariate and multivariate analyses of prognostic factors on overall survival in gastric cancerUnivariateMultivariateHR95% CI*p* valueHR95% CI*p* valueBackground Sarcopenia (+)1.891.34--2.640.00041.461.01--2.090.0454 Age ≥  75 years1.851.32--2.580.00051.641.13--2.370.0093 Sex, male1.000.70--1.440.9830 Comorbidity (+)1.731.20--2.550.00301.701.14--2.590.0086 ASA-PS ≥  III1.220.62--2.150.5406Tumor Histology (undifferentiated)1.691.22--2.340.00161.380.97--1.960.0726 T score ≥  24.273.00--6.20\< 0.00012.451.51--3.990.0003 N score ≥  13.652.63--5.13\< 0.00011.621.05--2.540.0289Operation Operation procedure (TG)2.531.81--3.51\< 0.00011.420.96--2.090.0789 Operation time ≥  300 min1.651.14--2.350.00801.631.08--2.430.0209 Blood loss ≥  500 mL1.921.36--2.690.00030.980.66--1.450.9316 Post-operative complications (+)1.611.13--2.270.00841.050.72--1.500.7937*HR* hazard ratio, *CI* confidence interval, *ASA*-*PS* American Society of Anesthesiologists physical status, *TG* total gastrectomy

Influence of Sarcopenia with Comorbidity on Non-Gastric Cancer-Related Death {#Sec9}
----------------------------------------------------------------------------

While sarcopenia and comorbidity were both independent prognostic factors of overall survival in gastric cancer patients (Table [2](#Tab2){ref-type="table"}), neither was an independent risk factor for non-gastric cancer-related death after gastrectomy (electronic supplementary Table 2). When sarcopenia and comorbidity were used as a combined marker, Kaplan--Meier survival analysis showed that sarcopenic patients with preoperative comorbidity had more non-gastric cancer-related death after gastrectomy than the other patients in our study population (*p*  =  0.0001); however, this combined marker was not associated with a significant survival difference for gastric cancer-related deaths (*p*  =  0.1134) (Fig. [2](#Fig2){ref-type="fig"}). Of the causes of non-cancer-related death, cardiovascular disease was the most frequent for sarcopenic patients with comorbidity (28%), while pneumonia was the most frequent for other patients (30%) (electronic supplementary Table 3). Multivariate analysis revealed that sarcopenia with comorbidity was an independent risk factor for non-cancer-related death after gastrectomy (HR 1.84, 95% CI 1.31--3.61, *p*  =  0.0308), as was age (Table [3](#Tab3){ref-type="table"}).Fig. 2Kaplan--Meier survival curve of gastric cancer patients with sarcopenia and comorbidity based on **a** overall death, **b** gastric cancer-related death, and **c** non-gastric cancer-related death Table 3Univariate and multivariate analyses of risk factors for non-gastric cancer-related deathUnivariateMultivariateHR95% CI*p* valueHR95% CI*p* valueBackground Sarcopenia with comorbidity2.561.53--4.190.00061.841.06--3.100.0308 Age ≥  75 years2.691.66--4.32\< 0.00012.181.31--3.610.0028 Sex, male1.851.03--3.620.03911.610.89--3.170.1171 ASA-PS ≥  III1.770.74--3.630.1845Tumor Histology (undifferentiated)0.810.49--1.320.4100 T score ≥ 21.631.01--2.620.04391.460.90--2.370.1245 N score ≥ 11.140.67--1.870.6192Operation Operation procedure (TG)1.360.78--2.270.2658 Operation time ≥  300 min1.320.74--2.270.3336 Blood loss ≥  500 mL1.630.97--2.680.0668 Post-operative complications (+)1.640.98--2.680.0603*HR* hazard ratio, *CI* confidence interval, *ASA*-*PS* American Society of Anesthesiologists physical status, *TG* total gastrectomy

Discussion {#Sec10}
==========

We used CT scans to evaluate sarcopenia as CT results are reliable and accurate. Although CT imaging is costly and invasive, it is particularly appropriate for retrospective studies such as this. SMA at the third lumbar vertebrae is often used for the assessment of sarcopenia.[@CR21] Although SMA divided by the square of height is used for sarcopenia index in many reports, there is concern that this index may be inappropriate for the detection of sarcopenic obesity, which is associated with higher risks of surgical complications, physical disability, and decreased survival.[@CR22] A previous report has shown SMA/BSA to be a more useful index for the definition of sarcopenia than SMA/height squared;[@CR23] therefore, to more effectively detect sarcopenic obesity, we used BSA for normalization and defined the lowest quartiles of the SMA/BSA index as sarcopenia. In this study population, the cut-offs were 69.7 cm^2^/m^2^ for males and 54.2 cm^2^/m^2^ for females, which may be useful as candidate cut-off values for future prospective studies of sarcopenia.

Many reports have suggested that sarcopenia is associated with poor outcomes in both the short and long term,[@CR12]^--^[@CR14],[@CR24],[@CR25] although others found no association between sarcopenia and postoperative morbidity and mortality.[@CR26] In their recent retrospective study of patients with esophagogastric junction cancer or upper gastric cancer who underwent gastrectomy, Kudou et al. reported that sarcopenia was strongly associated with poor long-term prognosis but not with short-term outcomes such as postoperative complications.[@CR15] These findings are similar to ours. We found that sarcopenia is not a risk factor for postoperative complications but is an independent prognostic factor. There have been few prospective interventional studies on sarcopenia, but Yamamoto et al. reported that preoperative exercise and nutritional support (median duration 16 days) for elderly sarcopenic patients with gastric cancer eliminated sarcopenia for 18.2% of these patients (4/22) and led to improvement in surgical outcomes.[@CR27] More prospective studies are needed to evaluate the benefit of exercise and nutritional support for sarcopenic patients, both before and after surgery.

In this study, we also investigated the association of sarcopenia with mortality from causes other than gastric cancer, and, to our knowledge, were the first to do so. We found that sarcopenic patients with comorbidity prior to surgery had a significantly higher risk of non-gastric cancer-related death after surgery compared with those without. However, neither sarcopenia nor comorbidity, when evaluated alone, significantly increased the risk of non-cancer-related death. This result may suggest the possibility that surgical stress worsened sarcopenia and led to non-cancer-related death resulting from comorbidity, and may be more important for patients with early-stage gastric cancer that can be cured by surgery.

While this study has contributed important information for clinical practice, it does have several limitations. First, this was a retrospective, single-center study and may have therefore suffered from selection bias. Second, although we showed the importance of sarcopenia with comorbidity on non-gastric cancer-related death after surgery, comorbidity actually varied from mild to severe, a spectrum that was not considered in our analysis. While ASA-PS is generally considered a good objective indicator of patient health, it did not emerge as a significant risk factor for non-gastric cancer-related death in this study. A better criterion for objective preoperative comorbidity assessment would therefore be helpful in future sarcopenia studies.

Loss of body weight following surgery has recently been identified as a poor prognostic factor for gastric cancer patients as it increases the risk of non-compliance with adjuvant chemotherapy.[@CR28] The prevention of postoperative weight loss has therefore become an important element for promoting better prognoses. However, Aoyama et al. reported that lean body mass loss was an independent risk factor for decreased adjuvant chemotherapy compliance, which suggests that the prevention of muscle mass loss may be more important than simple prevention of overall weight loss.[@CR29] In the setting of an aging population, more sarcopenic patients are expected to require surgery, and having a wider and deeper knowledge of sarcopenia and its effects may become very important to future medical management strategies for gastric cancer patients. Our findings emphasize the importance of considering both clinical and pathological factors, and weighing the benefits of surgical interventions carefully when designing a treatment strategy, as maximizing QOL is especially important for patients with low life expectancy.

Conclusions {#Sec11}
===========

In this study, we confirmed that, as several previous studies had reported, sarcopenia is an independent prognostic factor, and, moreover, that sarcopenia in combination with comorbidity is a risk factor for non-gastric cancer-related death after surgery. This latter seems to be a novel finding. Based on these results, we recommend the development of treatment strategies for gastric cancer that are based on both clinical (including sarcopenia and comorbidity) and pathological factors. We also recognize the likelihood that perioperative interventions, such as exercise and nutritional support to improve or prevent sarcopenia, are important for improving prognosis, although prospective studies are required to prove this.
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